X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AJANTA PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AJANTA PHARMA DR. REDDYS LAB/
AJANTA PHARMA
 
P/E (TTM) x 26.0 20.0 130.5% View Chart
P/BV x 3.2 4.6 69.4% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 DR. REDDYS LAB   AJANTA PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
AJANTA PHARMA
Mar-18
DR. REDDYS LAB/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7881,818 153.4%   
Low Rs1,9021,106 171.9%   
Sales per share (Unadj.) Rs860.8239.5 359.4%  
Earnings per share (Unadj.) Rs57.152.8 108.1%  
Cash flow per share (Unadj.) Rs122.059.5 205.0%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.7230.0 329.5%  
Shares outstanding (eoy) m165.9188.77 186.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.76.1 44.6%   
Avg P/E ratio x41.127.7 148.4%  
P/CF ratio (eoy) x19.224.6 78.2%  
Price / Book Value ratio x3.16.4 48.7%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,034129,782 299.8%   
No. of employees `00023.56.8 346.2%   
Total wages/salary Rs m32,1493,765 854.0%   
Avg. sales/employee Rs Th6,070.83,128.4 194.1%   
Avg. wages/employee Rs Th1,366.6554.0 246.7%   
Avg. net profit/employee Rs Th402.5689.7 58.4%   
INCOME DATA
Net Sales Rs m142,81021,258 671.8%  
Other income Rs m1,552242 642.4%   
Total revenues Rs m144,36221,499 671.5%   
Gross profit Rs m23,5126,584 357.1%  
Depreciation Rs m10,772596 1,807.7%   
Interest Rs m7884 19,219.5%   
Profit before tax Rs m13,5046,226 216.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3801,539 284.6%   
Profit after tax Rs m9,4684,686 202.0%  
Gross profit margin %16.531.0 53.2%  
Effective tax rate %32.424.7 131.2%   
Net profit margin %6.622.0 30.1%  
BALANCE SHEET DATA
Current assets Rs m104,98412,236 858.0%   
Current liabilities Rs m68,9383,461 1,992.1%   
Net working cap to sales %25.241.3 61.1%  
Current ratio x1.53.5 43.1%  
Inventory Days Days7460 123.5%  
Debtors Days Days10484 122.6%  
Net fixed assets Rs m104,38511,140 937.0%   
Share capital Rs m830177 469.2%   
"Free" reserves Rs m124,88620,237 617.1%   
Net worth Rs m125,71620,414 615.8%   
Long term debt Rs m25,08910 248,405.9%   
Total assets Rs m225,44324,486 920.7%  
Interest coverage x18.11,519.4 1.2%   
Debt to equity ratio x0.20 40,336.0%  
Sales to assets ratio x0.60.9 73.0%   
Return on assets %4.519.2 23.7%  
Return on equity %7.523.0 32.8%  
Return on capital %9.730.5 31.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62311,667 622.4%   
Fx outflow Rs m18,9161,616 1,170.9%   
Net fx Rs m53,70710,052 534.3%   
CASH FLOW
From Operations Rs m18,0302,854 631.7%  
From Investments Rs m-14,883-2,604 571.5%  
From Financial Activity Rs m-4,440-2 222,000.0%  
Net Cashflow Rs m-1,236248 -498.2%  

Share Holding

Indian Promoters % 25.5 73.8 34.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 1.6 348.4%  
FIIs % 35.3 7.6 464.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.0 90.0%  
Shareholders   75,885 20,968 361.9%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  SUVEN LIFE  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Retail Inflation, Growth in India's Aviation Sector, and Top Cues in Focus Today(Pre-Open)

Share markets in India witnessed buying interest during closing hours yesterday and ended the day on a positive note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 13, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS